抑郁症患者血清同型半胱氨酸水平的研究

目的　探讨同型半胱氨酸 (Homocysteine ,Hcy)在抑郁症发病中的作用。方法　采用荧光偏振免疫法 (FPLA)检测 2 2例抑郁症患者 (抑郁症组 )和 2 0名正常人 (对照组 )的血清Hcy水平 ,以 μmol/l计。 结果　抑郁症组血清Hcy水平高于对照组 [(16 .37± 6 .4 5 ) μmol/l比 (11.6 2± 4 .0 7) μmol/l,P <0 .0 1]。抑郁症组高同型半胱氨酸血症 (Hyperhomocysteinemia ,HHcy) (血清Hcy水平 >16 .0 0 μmlo/l)的发生率明显高于对照组 (4 5 .4 5 %比 10 .0 0 % ,oddsratio ,7.5 ;95 %可信区间 ,1.5 9～ 35 .39,P <0 .0 5 )。结论　抑郁症患者的血清Hcy水平升高 ,提示Hcy在抑郁症的发病中起一定作用。     

抑郁症患者血清同型半胱氨酸水平的研究

目的探讨抑郁症患者血清同型半胱氨酸水平与抑郁症发病的相关性。方法将94例抑郁症患者作为研究组,选取98例身心健康正常人为对照组,应用荧光偏振免疫法检测血清同型半胱氨酸水平。结果研究组患者血清同型半胱氨酸水平显著高于对照组(16.72±3.94)μmol/L,(10.99±3.51)μmol/L,P<0.05,研究组高同型半胱氨酸血症发生率显著高于对照组(41.5%,14.3%)(χ2=14.89,P<0.05)。结论血清同型半胱氨酸水平升高可能是抑郁症发病的重要危险因素之一,血清同型半胱氨酸水平对抑郁症严重程度有一定的影响。     

抑郁症患者血浆同型半胱氨酸水平的测定

目的:测定抑郁症患者及正常人血浆同型半胱氨酸(Hcy)水平,评价其意义. 方法:收集46例抑郁症(抑郁症组)及38名健康者(对照组)血液标本,采用高效液相色谱法测定血浆Hcy水平,放射免疫法测定血浆维生素B12和叶酸水平,比较两组间差异. 结果:抑郁症组血浆Hcy水平(13.2±6.2)μmol/L,显著高于对照组(7.6±2.4)μmol/L.抑郁症组平均血浆维生素B12水平为(334.0±5.7)ng/L,血浆叶酸水平为(5.9±4.0)μg/L;而对照组分别为(344.0±7.5)ng/L和(7.8±3.0)μg/L,均以抑郁症组显著较低(P<0.05). 结论:血浆Hcy水平升高可能与抑郁症有关.     

血清同型半胱氨酸水平对氟西汀治疗抑郁症疗效的影响

目的 探讨血清同型半胱氨酸对氟西汀治疗抑郁症疗效的影响.方法 应用荧光偏振免疫法(Fluo-rescence Polarization Immunoassay,FPIA)检测38例抑郁症患者血清同型半胱氨酸水平,并给予8周氟西汀系统治疗,分别于治疗前及治疗后第8周对患者进行17项汉密尔顿抑郁量表(Hamilton rating scale for depres-sion,HAMD17)评定.结果 治疗前抑郁症患者血清同型半胱氨酸水平为(16.45±5.96)μmol/L,高同型半胱氨酸血症的发生率为42.50%;治疗前HAMD评分为(28.38±2.91),与血清同型半胱氨酸水平呈正相关(r=0.724,P=0.000).经过治疗,全部样本中有显著疗效28例(占73.69%),有效8例(占21.05%),无效2例(占5.26%);HAMD减分率为(59.60±19.95)%,与治疗前患者的血清同型半胱氨酸水平呈负相关(r=-0.848,P=0.000).显效组、有效组和无效组患者治疗前血清同型半胱氨酸水平分别为(14.37±2.61)μmol/L,(21.86±3.55)μmol/L,(31.93±11.96)μmol/L,三组组间比较有显著性差异(P=0.000).高同型半胱氨酸血症组和非高同型半胱氨酸血症组患者HAMD减分率分别为(42.64±14.67)%和(73.33±11.03)%,两组比较有显著性差异(t=7.326,P=0.000).结论 血清同型半胱氨酸水平升高可能是抑郁症发病的重要危险因素之一,其对氟西汀治疗抑郁症患者的疗效有一定影响.     

药源性肥胖患者血清同型半胱氨酸水平研究

目的：了解抗精神病药所致药源性肥胖患者的血清同型半胱氨酸（Hcy）水平及其可能的影响因素。方法：调查60例药源性肥胖住院患者,用酶免疫法测定其血清Hcy水平,用化学发光法测定其血清叶酸、VitB12水平。以28名健康者为对照。结果1患者组血清Hey水平明显高于对照组（P〈0．001）,而血清叶酸、VitB12水平则显著低于对照组（P〈0．001及〈0．005）。单因素相关分析显示其血清Hcy与叶酸、VitB12呈负相关（r＝-0．520,P〈0．01;r：-0．372,P〈0．01）,多元逐步回归示叶酸是影响血清Hcv水平的因子（标准回归系数-0．490,t＝-5．16,P〈0．01）。结论：药源性肥胖患者多存在高同型半胱氨酸血症（HHcy）,其血清Hcy水平主要受叶酸的影响。     

脑卒中后抑郁患者血清同型半胱氨酸水平研究

脑卒中后抑郁(post-stroke depression,PSD)是以心境低落、兴趣下降等为特征的脑卒中常见并发症。其发生率为20%～60%[1],严重程度与脑卒中的预后密切相关,可明显增加患者死亡率。血同型半胱氨酸(HCY)水平升高近年被确定为脑卒中的独立危险因素[2],越来越受到人们的关注。但在脑卒中后抑郁症患者血清同型半胱氨酸水平的研究方     

精神分裂症患者血清同型半胱氨酸水平分析

目的探讨血清同型半胱氨酸（Hcy）水平变化与精神分裂症之间的关系。方法采用免疫散射比浊法对63例精神分裂症患者（研究组）及60名健康对照者（对照组）血清Hcy水平进行了检测。结果研究组血清Hcy水平及高同型半胱氨酸血症（HHcy）发生率均高于对照组（P〈0.01）。两组男性血清Hcy水平均高于同组女性（P〈0.05,P〈0.01）,不同性别血清Hcy水平比较,研究组均高于对照组（P〈0.01）;经典抗精神病药物组血清Hcy水平及HHcy发生率均高于非典型抗精神病药物组（P〈0.05）。结论血清Hcy升高可作为精神分裂症的实验室辅助诊断指标之一,血清Hcy水平存在性别间差异,临床应用时应分别设立不同参考区间。非典型抗精神病药物可能通过调节Hcy代谢并降低血清Hcy水平来改善患者认知功能。     

男性慢性精神分裂症患者血清同型半胱氨酸水平研究

<正>我们探索随着病程迁延血清Hcy水平在早发及非早发精神分裂症患者中变化及影响其关联因素,报告如下。1对象和方法为2011年10月在我院住院且长期服用抗精神药物治疗的男性慢性精神分裂症患者,共77例。入组标准:1符合国际疾病分类第10版精神分裂症诊断标准;2病程≥2年,且服药≥6个月,近期病情稳定;3年龄18~66岁。排除1心脏、肝脏、肾脏、内分泌、风湿、血液、消化道系统、营养不良     

血清同型半胱氨酸在双相障碍、精神分裂症和抑郁症中的表达

目的探讨血清同型半胱氨酸(Hcy)在双相障碍、精神分裂症和抑郁症患者中的水平。方法以2016年5月-10月在佛山市第三人民医院住院的符合《中国精神障碍分类与诊断标准(第3版)》(CCMD-3)诊断标准的双相障碍(168例)、精神分裂症(231例)和抑郁症患者(100例)为患者组,以同期佛山市第三人民医院的健康体检者112名作为对照组,采用循环酶法检测所有研究对象的血清Hcy水平。结果各组血清Hcy水平组内比较,男性均高于女性,差异均有统计学意义(P均0.05);双相障碍组和精神分裂症组血清Hcy水平均高于对照组和抑郁症组,差异均有统计学意义(P均0.05),但双相障碍组与精神分裂症组,对照组与抑郁症组间的血清Hcy水平差异均无统计学意义(P均0.05)。结论双相障碍和精神分裂症患者的血清Hcy水平均呈高表达,抑郁症患者血清Hcy水平未升高,Hcy水平可能存在性别差异。     

精神分裂症患者血清同型半胱氨酸水平的研究

目的观测精神分裂症患者同型半胱氨酸(homocysteine,Hcy)水平,并探讨其与精神病理症状的关系。方法采用病例-对照研究设计。用荧光偏振免疫法(FPLA)检测45例精神分裂症患者(患者组)和45名健康正常人(对照组)的血清Hcy,比较各类患者的Hcy。结果患者组血清Hcy水平[(17.3±5.6)μmol/L]高于对照组[(12±3.6)μmol/L],其高同型半胱氨酸血症(HHcy>17 μmol/L)的发生率明显高于对照组(42.2%比8.9%,Odds Ratio:7.5,95%可信区间为2.3-24.5,P=0.000)。阳性亚型患者Hcy水平[(15.6±4.9)μmol/L]低于阴性亚型患者[(20.4±5.6)mol/L],P<0.01。P因子高分亚组患者Hcy水平[(15.1±5.1)μmol/L]低于低分亚组患者[(19±5.6)μmol/L],P<0.05。Hcy水平与阳性症状总分呈负相关(r=-0.374.P<0.05),与阴性症状总分呈正相关(r= 0.297,P<0.05)。结论精神分裂症患者的血清Hcy水平升高,并与精神病理症状有关。     

Anger attacks in major depressive disorder and serum levels of homocysteine.

BACKGROUND: Increased levels of homocysteine have been associated with anger and depression separately. We investigated the association of anger attacks in major depressive disorder (MDD) with serum levels of homocysteine. METHODS: Homocysteine serum levels were measured in 192 outpatients with nonpsychotic MDD, mean age 39.9 +/- 10.7 (range 19-65), 53% women, at baseline of an open-trial antidepressant treatment. We used the Massachusetts General Hospital Anger Attacks Questionnaire to evaluate anger attacks, the Structured Clinical Interview for DSM-III-R Axis I Disorders-Patient Edition (SCID-I/P) to diagnose MDD and the 17-item Hamilton Rating Scale for Depression to measure depression severity. RESULTS: In the multiple regression analysis split by anger attacks adjusted for parameters of depression, creatinine, vitamin B(12), folate, age, smoking, and alcohol consumption, serum levels of homocysteine were positively correlated with length of current major depressive episode (t value, 3.01; 95% confidence interval [CI], .09 to .43; p = .004) and HAM-D-17 scores (t value, 2.48; 95% CI, .07 to 0.64; p = .016) in patients with anger attacks but not in those without anger attacks. CONCLUSIONS: Anger attacks in MDD may moderate the relationship of homocysteine serum levels with the severity and length of the depressive episode. Future studies are warranted to confirm and clarify the nature of this moderating effect.     

Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder

Objective

We assessed major cognitive domains in major depressive disorder (MDD) compared to a healthy control group using neurocognitive tests. We hypothesized that lower serum brain-derived neurotrophic factor (BDNF) levels would be associated with poorer neurocognitive performance in patients with major depression and that these associations would be shown in healthy controls as well.

Method

Executive functions, sustaining and focusing of attention, memory functions, and verbal fluency were assessed in this study using the Trail-Making Test (TMT), Stroop Color Word Interference Test-TBAG Form (SCWT), Wisconsin Card Sorting Test (WCST), Test of Variables of Attention (TOVA), Auditory Consonant Trigram test (ACTT), Digit Span subtest of the Wechsler Memory Scale (DST), Rey Auditory Verbal Learning Test (RAVLT), and Controlled Oral Word Association Test (COWAT).

Results

The MDD group showed significantly poorer performance than the control group in cognitive functions; they also had lower levels of BDNF than the control group. However, there was no correlation between cognitive performances and BDNF levels except in the TMT, Part B.

Conclusions

The current understanding of the importance of neurocognitive assessment and related biological markers in depression is improving. Further studies with larger sample sizes evaluating neurocognitive functions with molecular analyses of BDNF levels may reveal a novel marker for predicting and monitoring neurocognitive deficits in depression.     

Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder

A total of 62 patients with major depressive disorder were analyzed in the study. Patients were evaluated for 11 weeks in an open label design to investigate the differential effects of reboxetine, sertraline and venlafaxine on thyroid hormones. Serum thyrotrophin (TSH), thyroxine (T4) and free (f)T4 levels were measured before and after treatment. All groups showed significant improvement in HAM-D scores. TSH level significantly reduced and T4 level significantly increased in the reboxetine group, however TSH level significantly increased and T4 level significantly reduced in the sertraline group. Percent changes of TSH (p = 0.007) and T4 (p = 0.001) were significantly different between the reboxetine and sertraline groups. In the sertraline group, baseline TSH levels were correlated with response to treatment as determined by the change in HAM-D scores (p = 0.03, r = 0.648). There was a significant association between the percent changes in TSH values and the reduction in HAM-D scores in the reboxetine group (p = 0.03, r = − 0.434). In the whole study group, female patients had lower values of basal T4 compared with men (p = 0.043), however percent changes of T4 did not differ between genders. In the treatment-responders significant increase in the reboxetine group and significant decrease in the sertraline group regarding the T4 values were found. We observed that various antidepressants had different effects on thyroid hormone levels and this could be attributed to the different mechanisms of actions of these antidepressants.     

Higher serum VGF protein levels discriminate bipolar depression from major depressive disorder

Misdiagnosis between major depressive disorder (MDD) and bipolar depression (BD) is quite common. Our previous study found significantly lower serum VGF (non-acronymic) in MDD patients. However, it is unclear whether same changes occur in BD patients. Therefore, we aimed to investigate the relationship between serum VGF levels in BD and MDD patients. General information, scores of 17-item Hamilton Depression Rating Scale (HDRS), and fasting blood samples of all participants including 30 MDD patients, 20 BD patients, and 30 healthy controls (HC) were collected. Serum VGF levels were measured by Enzyme-linked immunosorbent assay kits. Pearson correlation analysis was used to analyze correlations between serum VGF levels and clinical information. Receiver operating characteristic (ROC) curve and likelihood ratios (LRs) were used to analyze the differential potential of serum VGF. Serum VGF levels were significantly lower in MDD patients but higher in BD patients compared with HC (both P_Tukey < 0.01). No correlation was found between serum VGF levels and any data of subjects. The optimal cutoff for serum VGF in discriminating BD patients from MDD patients was ≥1093.85 pg/ml (AUC = 0.990, sensitivity of 95%, specificity of 100% and accuracy of 95%). LRs further confirmed the differential efficiency of serum VGF in distinguishing BD and MDD patients with +LR of infinity and –LR of 0. The results suggest that serum VGF level changed significantly in MDD and BD patients and serum VGF may be an indicator for differentiating BD patients from MDD patients.     

Blood levels of cytokines in elderly patients with major depressive disorder

Plasma concentrations of interleukin-iβ (IL-lβ), interleukin-6 (IL-6) and tumour necrosis factor a (TNFα) were measured in 10 elderly women with major depressive disorder (MDD) and in two groups of controls, one consisting of 10 age-matched healthy female volunteers and one consisting of 10 young healthy female volunteers. The cytokine concentrations were measured in MDD patients before and after 30 days of treatment with phosphatidylserine (BC-PS), 600 mg daily p.o. The plasma IL-1β IL-6 and TNFα concentrations did not differ significantly in young controls, elderly controls and MDD patients. BC-PS therapy, while significantly improving the depressive symptoms, did not alter the cytokine concentrations.     

One-year outcome of elderly inpatients with major depressive disorder treated with ECT and antidepressants

We report the acute response and outcome in 1-year follow-up of 51 elderly depressive inpatients with major depressive disorder treated with electroconvulsive therapy (ECT) (n = 30) and/or antidepressant therapy (n = 21). The patients were assessed at admission, at discharge, and after 1 year according to the Montgomery and Asberg Depression Rating Scale, the Beck Depression Inventory, and the Clinical Global Impression Scale. The acute response was good. Montgomery and Asberg Depression Rating Scale total scores diminished significantly during index hospitalization within both groups (from 31.6 +/- 8.5, to 8.1 +/- 6.0 in the ECT group and from 28.5 +/- 5.4 to 13.4 +/- 10.6 in the antidepressant group). The 1-year rehospitalization rate for the entire group, however, was 21 of 51 patients (41%), 13 of 30 patients (43%) in the ECT group, and 8 of 21 (38%) in the antidepressant group. Six of 13 patients in the ECT group and 1 of 8 patients in the antidepressant group were rehospitalized during the first month after discharge. The results suggest a good acute therapeutic response to both ECT and antidepressive therapy in elderly patients with MDD. The major finding in this study was the relatively high rehospitalization rate, which emphasizes the need for careful follow-up of the elderly patients who have recovered from a depressive episode.     

Decreased serum BDNF levels in major depressive patients

Background

Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal plasticity. The aim of the present study was to measure serum BDNF levels in depression and to analyze the relationship between BDNF levels and severity of depression.

Methods

Thirty patients meeting the DSM-IV criteria for major depressive disorder and 40 normal control subjects were recruited for this study. Patients had not used psychotropic drugs. The severity of depression was assessed by the Hamilton Rating of Depression Scale (HAM-D). Serum BDNF levels were determined by using ELISA.

Results

HAM-D scores were 17.09 ± 4.96 in depressed patients. We determined that the serum BDNF levels of the depression patients were lower than those of the healthy control group (respectively, 1453.42 ± 144.51 pg/ml, 1632.23 ± 252.93 pg/ml, t = 3.467, p = 0.001, independent t test). No correlation was found between the patients’ serum BDNF levels and HAM-D scores (p > 0.05, Pearson correlation analysis).

Conclusions

Our results suggest that serum BDNF levels are low in depression. However it was not found association between serum BDNF levels and the severity of depression.